Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (June 2019)
29 slides from Qiagen's investor day presentation, Jun 20, 2019
Slide 1: Strategy update
2019 Analyst & Investor Day Strategy update Executing on exciting Sample to Insight portfolio opportunities Peer Schatz Chief Executive Officer Sample to Insight
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate statements. All statements other than statements of historical fact are, or may be deemed to be (CER) basis,
Slide 3: QIAGEN: Capturing dynamic growth opportunities in the century of biology
QIAGEN: Capturing dynamic growth opportunities in the century of biology Fueling the genomics One of the most revolution with disruptive trusted brands in technologies molecular testing Highly focused leadership Agile commercial spanning the continuum teams with from Life Sciences to global reach an
Slide 4: World leader in providing Sample to Insight solutions for molecular testing
World leader in providing Sample to Insight solutions for molecular testing 2018 net sales (as % of total QIAGEN sales) QIAGEN customer classes Product portfolio Global sales ~32% ~33% Academia / Europe / Applied ~46% Middle East / Testing Americas ~49% Africa Molecular ~51% Diagnostics Life Science
Slide 5: Dynamic and disruptive portfolio to unlock valuable molecular insights
Dynamic and disruptive portfolio to unlock valuable molecular insights Sample Technologies Assay Technologies Advancing understanding of life Faster and better drug R&D Better diagnoses Sample to Insight solutions Ensuring public safety Automation systems Bioinformatics VALUABLE BIOLOGICAL MOLECULAR
Slide 6: Global presence with focus on most attractive markets and presence in over 85 countries
Global presence with focus on most attractive markets and presence in over 85 countries Sollentuna Distribution Venlo Aarhus partners Manchester Wroclaw Toronto Stockach Hilden in over 60 Beverly Milan Seoul Paris Ankara Beijing Redwood City Frederick Waltham Madrid Tokyo countries New Cairo Germant
Slide 7: Well-positioned to use focus, agility and size to capitalize on attractive market opportunities
Well-positioned to use focus, agility and size to capitalize on attractive market opportunities Aging society and Dramatic pace rapidly growing of scientific healthcare costs breakthroughs Increasing and Increasingly Growing disseminating complex data demand for use of driving better patient molecul
Slide 8: Fully engaged in rapidly growing areas of science and clinical applications
Fully engaged in rapidly growing areas of science and clinical applications Sample to Insight 2019 Analyst & Investor Day 8
Slide 9: Significant progress on mid-term targets set in 2016 as part of QIAGEN transformation
Significant progress on mid-term targets set in 2016 as part of QIAGEN transformation Net sales growth trends Adjusted diluted EPS trends Operating cash flow trends At constant exchange rates to comparative year In $ per share In $ millions Total CER growth Organic growth ~+7-8% 1.45-1.47 7% CER CER
Slide 10: Scorecard on 2016-2020 targets
Scorecard on 2016-2020 targets 2016 – 2020 targets Results since 2016 2016 Building momentum • Accelerating growth Net sales • Moving into sales growth target range (excluding divestments and acquisitions) (~+7-9% CER CAGR Sample to Insight portfolio transforming QIAGEN: 2016-2020) • QuantiFERON-TB:
Slide 11: Positioned for an exciting growth cycle after multi-year transformation while achieving targets
Positioned for an exciting growth cycle after multi-year transformation while achieving targets Since 2016 2019-2023 strategic ambitions Significantly improved capabilities Moving into growth and value creation cycle Created agile and strong organization Realigned commercial engine Multiple launches
Slide 12: Delivering growth acceleration, margin expansion and disciplined capital allocation
Delivering growth acceleration, margin expansion and disciplined capital allocation 2018 results 2019 outlook 2019-2023 targets Sales growth +6% CER ~+7-8% CER ~+8-9% CER CAGR(1) Adjusted operating income margin 27% ~27% CER ~29% CER Adjusted diluted EPS $1.34 ~$1.45-1.47 CER ≥+10% CER CAGR(2) 2020-
Slide 13: Strategy: On a trajectory to deliver faster growth, increase returns and create greater value
Strategy: On a trajectory to deliver faster growth, increase returns and create greater value Expand leadership and leverage Sample to Insight portfolio opportunities New 2019-2023 targets for above-market sales growth Maximizing Deliver on multiple automation platform launches and growth initiative
Slide 14: 2023 targets: Strengthen leadership in exciting areas of evolving molecular testing market
2023 targets: Strengthen leadership in exciting areas of evolving molecular testing market Sample to Insight portfolio QIAGEN (Market share / growth profile) 2023 sales target Academia / Sample Technologies ~60% Applied ~15% Assay Technologies / PCR ~10% Testing 2019 Assay Technologies / NGS ~15% ~4
Slide 15: Executing new product launches to capture growth in >$4 billion of market opportunities
Executing new product launches to capture growth in >$4 billion of market opportunities 2018 2019 2020 2021 2022 2023 >$1 billion market QuantiFERON automation partnerships and menu expansion QFT DiaSorin EU QFT DiaSorin U.S. >$800 million market QIAstat-Dx menu expansion QIAstat-Dx EU QIAstat-Dx U.
Slide 16: Sample Technologies
Developments since 2016 2019-2023 ambitions • Strengthened Nr. 1 position – • Extend market and technology leadership with first step in virtually any biology lab process innovations in high-demand application areas Sample • >500 sample technology kits now available ◦ Examples: Liquid biopsy, microb
Slide 17: Digital PCR
Developments since 2016 2019-2023 ambitions • Developing next-generation digital PCR platform • Planning 2020 launch into research market based on technology acquired from Formulatrix ◦ >$200 million market opportunity (2019) • Adapting vast quantitative PCR assay portfolio with >+20% annual CER gro
Slide 18: Next-generation sequencing
Developments since 2016 2019-2023 ambitions • Exceeded $150 million sales in 2018 • Targeting >$190 million CER sales in 2019 • Rapid growth of “Digital NGS” gene panels) ◦ Expect strong double-digit CER growth rate ◦ >100 preconfigured panels available (QIAseq, • Expand range of NGS panels for use
Slide 19: Human Identification / Forensics
Developments since 2016 2019-2023 ambitions • Strengthened No. 1 sample technologies portfolio • 2023 goal: >$90 million sales (2018: ~$60 million) ◦ Includes collection, stabilization, isolation, • Strengthen sample collection and processing as purification and storage of DNA/RNA samples well as da
Slide 20: Immune Response: QuantiFERON
Developments since 2016 2019-2023 ambitions • On track for $300 million sales goal in 2020 • New 2023 target: >$400 million CER of QFT sales Immune ◦ Increased >90% share as modern standard ◦ Launch QFT-TB Access in 2020, gain access to Response: for latent TB testing against numerous competitors hi
Slide 21: Infectious Diseases: QIAsymphony
Developments since 2016 2019-2023 ambitions • Exceeded 2,300 cumulative placements in 2018 • Goal for >200 annual placements through 2023 • Successful regionalization strategy • Continue regionalization strategy ◦ US: focus on sample technologies ◦ US: focus on sample technologies ◦ ROW: sample tech
Slide 22: Infectious Diseases: QIAstat-Dx
Developments since 2016 2019-2023 ambitions • Entered $800 million market with >20% CER growth • Drive global market penetration and share gain ◦ On track for 2019 goal of >$30 million sales • Aggressive menu expansion, >8 panels by 2021 Infectious • EU launch in late 2018 with 300 placements • Expa
Slide 23: Infectious diseases: NeuMoDx
Developments since 2016 2019-2023 ambitions • Entered $2.7 billion market opportunity for fully • Achieve menu with 11 CE-IVD tests by end-2019 integrated PCR-based platforms • Further develop infectious disease menu and Infectious ◦ Synergy with modular QIAsymphony as well as consider new applicati
Slide 24: Oncology and Precision Medicine
Developments since 2016 2019-2023 ambitions • Strengthened leadership in molecular CDx • Growth in pharma co-development revenues ◦ >25 pharma partnerships ◦ 2018 co-development revenues: $58 million ◦ >50 active development programs • Expansion of CDx assay portfolio in clinical labs ◦ Developing N
Slide 25: Capital deployment: Reaffirming commitment to balanced and disciplined approach
Capital deployment: Reaffirming commitment to balanced and disciplined approach Business Sustainable and profitable growth with reinvestments a dynamic new product portfolio Capital Value- Strategic acquisitions and collaborations allocation enhancing to enhance Sample to Insight portfolio strategy
Slide 26: ESG: Ensuring sustainable business development as part of value creation strategy
ESG: Ensuring sustainable business development as part of value creation strategy Environment Social Governance Reducing environmental impact Building diversity for competitive edge Ensuring the highest standards • Target reduction in packaging • Global approach to inclusion • Compliance activities
Slide 27: Our employees: Driving our market leadership and quality reputation
Our employees: Driving our market leadership and quality reputation New image Sample to Insight 2019 Analyst & Investor Day 27
Slide 28: Leadership: International team with extensive industry experience
Leadership: International team with extensive industry experience Executive Committee Supervisory Board CEO Molecular Diagnostics Håkan Björklund Chair Peer Schatz Thierry Bernard Supervisory Board Joined 1993 Joined 2015 Joined 2017 Human Resources Commercial Operations Metin Colpan Chair Manuel O.
Slide 29: Summary
Summary • Executing on exciting Sample to Insight portfolio opportunities • Launching disruptive new solutions to gain market share in dynamic markets • Reinforcing value creation with efficiency and disciplined capital allocation • Developing talented, inclusive teams to deliver sustainable growth